Studies of the efficacy of Ribonucleotide Reductase inhibition in preclinical models of Acute Myeloid Leukemia in combination with standard and novel therapeutics
type: CreativeWork
description: Acute Myeloid Leukemia (AML) is an aggressive disease of the marrow with approximately 18,800 new cases each year. The elderly population represents the bulk of AML patients with a median age of onset of 70. More than 70% of AML patients are over the age of 60, and for this group the 5 year overall survival rate is under 10%. There are multiple reasons for this, including complex karyotypes in elderly patients, other comorbidities, and chemoresistance. This group of patients needs more effective chemotherapeutic options.
abstract: Acute Myeloid Leukemia (AML) is an aggressive disease of the marrow with approximately 18,800 new cases each year. The elderly population represents the bulk of AML patients with a median age of onset of 70. More than 70% of AML patients are over the age of 60, and for this group the 5 year overall survival rate is under 10%. There are multiple reasons for this, including complex karyotypes in elderly patients, other comorbidities, and chemoresistance. This group of patients needs more effective chemotherapeutic options.
author: Cook, Guerry
language: en
keywords: Acute Myeloid Leukemia
date published: 2015
date modified: 2026-07-27T22:01:52Z
provider: Wake Forest University
publisher: Networked Digital Library of Theses and Dissertations
type: WebPage
source organization: Wake Forest University

PropertyValue
property ID: Handle
value: http://hdl.handle.net/10339/57136